Xtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with a 12% revenue increase, improved gross margins, and a turnaround to net income. Despite a 5% rise in operating expenses, cash flow from operations increased significantly. The absence of strategic or operational updates limits the upside, but the financial metrics alone suggest a positive sentiment. No critical concerns were raised in the Q&A. Given these factors, a positive stock price movement of 2% to 8% is expected over the next two weeks.
Key Financial Performance
Revenue Revenue for Q4 2025 was $18.2 million, representing a 12% increase year-over-year. This growth was driven by strong demand for the company's core products and successful execution of sales strategies.
Gross Margin Gross margin for Q4 2025 was 65%, up from 62% in Q4 2024. The improvement was attributed to better operational efficiencies and cost management.
Net Income Net income for Q4 2025 was $2.5 million, compared to a net loss of $0.8 million in Q4 2024. This turnaround was due to increased revenue and improved gross margins.
Operating Expenses Operating expenses for Q4 2025 were $8.5 million, a 5% increase year-over-year. The rise was primarily due to higher investments in R&D and marketing initiatives.
Cash Flow from Operations Cash flow from operations for Q4 2025 was $3.2 million, up from $2.0 million in Q4 2024. The increase was driven by higher net income and better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Management made forward-looking statements regarding future events and the company's expected future performance, which involve risks and uncertainties. These statements are not guarantees of future performance and actual results may differ materially.
Regulatory risks: Risks and uncertainties are noted in the Risk Factors section of the company's annual report on Form 10-K filed with the SEC and in subsequent SEC reports and press releases.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisors Form
BTIG LLC
Browne President
CEO Director
Capital Group
Craig Hallum
Director Scott
Division Chase
Division Xtant
EDT Iseult
Full Financial
Group LLC
Hallum Capital
Holdings Inc
Inc Sean
Instructions conference
Iseult McMahon
Knickerbocker Craig
LLC Research
LifeSci Advisors
McMahon BTIG
Medical Full
Medical Holdings
Neils Chief
Officer EDT
President CEO
Research Division
Results Instructions
Scott Neils
Sean Browne
Xtant Medical
XTNT Transcript
Xtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call Transcript
Positive3-31
The earnings call reveals strong financial performance with a 12% revenue increase, improved gross margins, and a turnaround to net income. Despite a 5% rise in operating expenses, cash flow from operations increased significantly. The absence of strategic or operational updates limits the upside, but the financial metrics alone suggest a positive sentiment. No critical concerns were raised in the Q&A. Given these factors, a positive stock price movement of 2% to 8% is expected over the next two weeks.
Xtant Medical Holdings, Inc. (XTNT) Q3 2025 Earnings Call Transcript
Positive11-11
The company reported strong financial results, including a 19% revenue increase and a shift from a net loss to a net income, coupled with improved gross margins and reduced operating expenses. The raised revenue guidance and strategic moves like asset sales and increased sales force indicate optimism. Despite some concerns about inventory and reliance on cost-cutting, the positive guidance and strategic focus on profitability and cash generation suggest a positive stock reaction.
Xtant Medical Holdings, Inc. (XTNT) Q2 2025 Earnings Call Transcript
Positive8-12
Xtant Medical's earnings call presents a positive outlook with a strong financial performance, including an 18% revenue increase and improved gross margins. The strategic focus on biologics and vertical integration, along with cost-cutting measures, enhances profitability. Despite some uncertainties in licensing revenue and regulatory risks, the optimistic 2025 guidance, new product launches, and improved cash flow from asset sales contribute to a positive sentiment. The Q&A reveals cautious optimism, with management addressing concerns about future licensing revenue. Overall, the company's strategic moves and financial performance suggest a positive stock price movement.
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2025 Earnings Call Transcript
Positive5-13
The earnings call indicates strong financial performance, including record revenue growth and improved profitability metrics. Despite competitive pressures and regulatory uncertainties, the company anticipates mid-double-digit growth in biologics and improved margins from in-house production. The lack of a shareholder return plan is a minor negative, but the overall financial outlook and strategic initiatives, such as vertical integration, suggest a positive stock price movement in the short term.
XTNT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
